Price sold off to eight-month lows before snapping back nearly 15%, bouncing from $122 to $132 and reclaiming its lost trendline. Volume remains tepid, raising the risk of a rug pull without follow-through. ETF flows show ARK adding roughly 85,500 shares, and prediction markets assign better-than-even odds to another up close, offering a bounce against recent sector weakness.

Q4 revenue rose 70% YoY to $1.4 B, led by 93% U.S. and 137% U.S. commercial growth. LTM profit margins hit 32%, GAAP net income margin reached 43%, and free cash flow margin topped 50%. Remaining deal value stood at $4.38 B. Full-year 2026 guidance calls for $7.18–7.20 B in revenue (≈61% growth). Patent awards and ample share-issuance headroom bolster AI platform expansion.

Legal NOL carryforwards, R&D deductions and stock-compensation write-offs allow Palantir to report zero U.S. federal income tax despite profits. It holds defense and public-sector data-processing contracts in the U.S., U.K., Israel, France and New Zealand under frameworks like Project Maven and FISA 702, triggering parliamentary review, CLOUD Act exposure and union resistance over patient data. Rare-earth supply disruptions threaten battlefield-intelligence platforms, while emerging AI contenders (Anthropic, OpenAI) and evolving trade regimes shape competitive and regulatory bottlenecks.

Investor optimism is buoyed by bullish political endorsements, high-profile fund buying, and confidence in Palantir’s entrenched defense AI moat, while lingering concerns over its premium valuation, government‐contract reliance, and rising AI competition keep sentiment tempered.